. 2023 May 28;41(8):981–997. doi: 10.1007/s40273-023-01277-4

Table 6.

Model input parameters for estimation of costs and effects related to MammaPrint^® and endocrine therapy: Costs input parameters (costs in Euros)

Direct health care costs
	Once	SE	Alpha	Beta	Source
MammaPrint^® costs	€2674	fixed	n.a.	n.a.	[32]
Endocrine therapy	Per cycle	SE
Average of AIs	€31.03	3.10^a	100	0.31	[33]
Tamoxifen (generic)	€19.11	1.91^a	100	0.19
Ovarian suppression—first cycle 3 injections per cycle	€908.91	90.9^a	100	9.09
Ovarian suppression—subsequent cycles 1 injection per cycle	€302.97	30.3^a	100	3.03

Minor adverse event costs
	Per cycle	SE	Alpha	Beta	Source
Vasomotor	€22.17	0.22^a	100	0.22	[39] + assumptions
Vulvovaginal	€22.17	0.22^a	100	0.22
Mood	€22.17	0.22^a	100	0.22
Cognitive	€22.17	0.22^a	100	0.22
	Once	SE	Alpha	Beta	Source
Fractures	€5486	€1321^b	16	343	[46] (once)

Major adverse event health care costs
	Once	SE	Alpha	Beta	Source
Thromboembolic events	€4459	€1130^b	16	279	[47]
Endometrium cancer	€15,292	€562	739	21	[48]
Other malignancies	€29,897	€7474^b	16	1869	[49–51]
Indirect health care costs
	Per cycle	SE	Alpha	Beta	Source
Indirect medical costs	Based on PAID 3.0	n.v.	n.a.	n.a.	[34]
End-of-life costs	Based on PAID 3.0	n.v.	n.a.	n.a.	[34]

Patient and family costs
	Per cycle	SE	Alpha	Beta	Source
Travel costs
Patients with minor AEs	€4.64	€0.46^a	100	0.05	[17]
Informal care costs
Patients who died from major AEs	€2680	€670^b	16	168	[52]

Costs made in other sectors
	Per cycle	SE	Alpha	Beta	Source
Costs due to productivity losses for patients treated with ET with related AEs —first 3 months	€3094	€656	22	139	TOTAM study (see Supplemental file 7) [28, 29]
Costs due to productivity losses for patients treated with ET-related AEs —next 3 months	€907	€348	7	133
Costs due to productivity losses for patients treated with ET-related AEs —subsequent months	€846	€342	6	138
Costs due to productivity losses for patients without ET-related AEs —first 3 months	€320	€320	1	320
Costs due to productivity losses for patients without ET-related AEs — 3–6 months	€346	€163	5	77
Costs due to productivity losses for patients without ET-related AEs—subsequent months	0	€0.5	1	250
Cost due to productivity losses for patients who died from major adverse events	€3501	€875	16	219	(costs of 1 friction costs period = 102 days) [17]
Non-medical consumption costs in life years gained
Non-medical consumption costs for each age ≥63 y	Based on PAID 3.0	n.v.	n.a.	n.a.	[34]

AEs adverse events, AIs aromatase inhibitors (anastrozole, letrozole, exemestane), ET endocrine therapy, n.a. not applicable, n.v. not varied, PAID Practical Application to Include Disease Costs

^aSE assumed to be 10% of mean

^bSE assumed to be 25% of mean